BACKGROUND AND OBJECTIVES: Microwave thermosphere ablation (MTA) is a new technology that is designed to create spherical zones of ablation using a single antenna. The aim of this study is to assess the results of MTA in a large series of patients. METHODS: This was a prospective study assessing the use of MTA in patients with malignant liver tumors. The procedures were done mostly laparoscopically and ablation zones created were assessed for completeness of tumor response, spherical geometry and recurrence on tri-phasic CT scans done on follow-up. RESULTS: There were a total of 53 patients with an average of 3 tumors measuring 1.5 cm. Ablations were performed laparoscopically in all but eight patients. Morbidity was 11.3% (n = 6), and mortality zero. On postoperative scans, there was 99.3% tumor destruction. Roundness indices A, B, and transverse were 1.1, 1.0, and 0.9, respectively. At a median follow-up of 4.5 months, incomplete ablation was seen in 1 of 149 lesions treated (0.7%) and local tumor recurrence in 1 lesion (0.7%). CONCLUSIONS: The results of this series confirm the safety and feasibility of MTA technology. The 99.3% rate of complete tumor ablation and low rate of local recurrence at short-term follow up are promising.
BACKGROUND AND OBJECTIVES: Microwave thermosphere ablation (MTA) is a new technology that is designed to create spherical zones of ablation using a single antenna. The aim of this study is to assess the results of MTA in a large series of patients. METHODS: This was a prospective study assessing the use of MTA in patients with malignant liver tumors. The procedures were done mostly laparoscopically and ablation zones created were assessed for completeness of tumor response, spherical geometry and recurrence on tri-phasic CT scans done on follow-up. RESULTS: There were a total of 53 patients with an average of 3 tumors measuring 1.5 cm. Ablations were performed laparoscopically in all but eight patients. Morbidity was 11.3% (n = 6), and mortality zero. On postoperative scans, there was 99.3% tumor destruction. Roundness indices A, B, and transverse were 1.1, 1.0, and 0.9, respectively. At a median follow-up of 4.5 months, incomplete ablation was seen in 1 of 149 lesions treated (0.7%) and local tumor recurrence in 1 lesion (0.7%). CONCLUSIONS: The results of this series confirm the safety and feasibility of MTA technology. The 99.3% rate of complete tumor ablation and low rate of local recurrence at short-term follow up are promising.
Authors: Thomas J Vogl; Andrei Roman; Nour-Eldin A Nour-Eldin; Wolfgang Hohenforst-Schmidt; Iliana Bednarova; Benjamin Kaltenbach Journal: Diagn Interv Radiol Date: 2018 Jan-Feb Impact factor: 2.630
Authors: R Rhaiem; R Kianmanesh; M Minon; A Tashkandi; A Aghaei; G Ledoux; Ch Hoeffel; O Bouche; D Sommacale; T Piardi Journal: World J Surg Date: 2020-05 Impact factor: 3.352
Authors: P Hendriks; W E M Berkhout; C I Kaanen; J H Sluijter; I J Visser; J J van den Dobbelsteen; L F de Geus-Oei; A G Webb; M C Burgmans Journal: Cardiovasc Intervent Radiol Date: 2021-01-18 Impact factor: 2.740
Authors: Luís Filipe Abreu de Carvalho; Bram Logghe; Stijn Van Cleven; Aude Vanlander; Suzane Moura Ribeiro; Karen Geboes; Clarisse Lecluyse; Peter Smeets; Helena Degroote; Hans Van Vlierberghe; Frederik Berrevoet Journal: Langenbecks Arch Surg Date: 2021-06-02 Impact factor: 3.445